BRIEF-Theravance and Alfa Wassermann enter agreement on gastroparesis drug

Oct 2 (Reuters) - Theravance Inc :

* Theravance and alfa wassermann enter into agreement to develop and

commercialize velusetrag for gastroparesis

* Says companies will collaborate in the execution of a two-part phase 2


* Says financial terms of the transaction include funding of the phase 2

program by alfa wassermann

* Says is entitled to receive royalties on net sales by alfa wassermann ranging

from the low teens to 20%.

* Theravance-financial terms of deal include potential development, regulatory

and sales milestone payments of up to $53.5 million

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))